Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SCD | O00767 | 7/20 | 0.37 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.36 |
| ▸ | HRH3 | Q9Y5N1 | 5/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3987087 | 1.00 | TDP1 (0.48) | TDP1ALDH1A1MAPTSCDKCNJ1 | |
| SCHEMBL28379280 | 0.77 | HRH3 (0.37) | TDP1ALDH1A1MAPTSCDHRH3 | |
| SCHEMBL28374701 | 0.77 | HRH3 (0.37) | TDP1ALDH1A1MAPTSCDHRH3 | |
| SCHEMBL28374702 | 0.77 | HRH3 (0.37) | TDP1ALDH1A1MAPTSCDHRH3 | |
| SCHEMBL3982871 | 0.75 | HRH3 (0.46) | ALDH1A1HRH3 | |
| SCHEMBL3982869 | 0.75 | HRH3 (0.46) | ALDH1A1HRH3 | |
| SCHEMBL29225079 | 0.73 | IDO1 (0.31) | — | |
| SCHEMBL28380492 | 0.71 | HRH3 (0.38) | SCDHRH3 | |
| SCHEMBL28374940 | 0.70 | GAA (0.37) | TDP1ALDH1A1MAPTSCDHRH3 | |
| SCHEMBL28374938 | 0.70 | GAA (0.37) | TDP1ALDH1A1MAPTSCDHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | ACTELION PHARMACEUTICALS, LTD. (CH) | 2009-04-02 | — | — | US | disclosed |
| EP-2029542-A2 | PRIMARY AMINES AS RENIN INHIBITORS | Actelion Pharmaceuticals Ltd. (CH) | 2009-03-04 | — | — | EP | disclosed |
| WO-2007099509-A2 | PRIMARY AMINES AS RENIN INHIBITORS | ACTELION PHARMACEUTICALS LTD (CH) | 2007-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090088457-A1 | Primary Amines as Renin Inhibitors | REN, ACE, AGTR1 | TDP1 2457/4885ALDH1A1 1144/4885MAPT 1268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.